Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema

Navenibart was well tolerated and substantially reduced HAE attacks, providing support for every-3-month and every-6-month administration of navenibart to prevent HAE attacks.